For anyone in Hamilton or elsewhere in Canada looking at Retatrutide as a research peptide, Id tell you to read the clinical data carefully and make an informed call
Persistent, distressing thoughts about food can also overlap with disordered eating, which the term food noise doesnt capture.1 If that sounds familiar, speaking to a professional is the right next step, whether or not youre taking a GLP-1 medication
Long-Term Safety: What We Know and Don't Know What We Know (From TRIUMPH-4 and TRIUMPH-1) Up to 80 weeks of data: Side effects improve significantly after dose escalation (first 16 weeks hardest) No unexpected safety signals in either trial Dysesthesia doesn't worsen over time (stable) Discontinuation rates stabilize (most who stop do so in first 24 weeks) No deaths attributed to retatrutide in any completed trial TRIUMPH-1 104-week extension shows continued weight loss without new safety signals What We Don't Know Yet Longer-term questions (need 25+ years data): Does dysesthesia resolve completely if medication stopped
While there are several reasons you may not be seeing your desired results from a GLP-1, new research points to a cause that might not be on your radar yet: your genes
For research organizations, access to reliable analytical information provides greater confidence when evaluating peptide materials for laboratory and development applications
Moreover, drugs with greater efficacy are being developed by combining two or three of GLP-1 and GIP or glucagon or amylin